Abstract: The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface receptor, such as a folate receptor. The cell surface folate binding compound can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor, e.g., folate receptor. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided herein are methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.

Abstract: A utility vehicle is configured for off-road terrain and may include a plurality of mounting members configured to support a load and/or support the vehicle during transport. The utility vehicle also includes an upper frame assembly which is movable between a first position and second position. The upper frame assembly may be moved to the second position during transportation of the utility vehicle. Further, the utility vehicle includes a plurality of configurations for a rear cargo area, thereby allowing for passengers or cargo to be supported.

Abstract: Techniques described herein include providing payment and access infrastructure for an array of transportation services, such as a set of transit or mobility services that might be provided by one or more governments, public agencies, and/or other public entities. In one example, this disclosure describes a method that includes enabling, by a computing system, a user to register for mobility benefits using a verification system, wherein the mobility benefits are provided by a provider entity; receiving, by the computing system and from the verification system, information about the user; establishing, by the computing system, an account linked to the provider entity; detecting, by the computing system, a request to access mobility benefits; allocating, by the computing system, funds from the account to pay for the mobility benefits.

Abstract: A mass spectrometer includes at least one ion guide having an inlet for receiving a plurality of ions from an upstream ion source and an outlet through which ions exit the ion guide, an ion routing device having an inlet for receiving at least a portion of the ions exiting the ion guide and at least two outlets, a first mass spectrometer positioned relative to the first outlet to receive ions exiting the ion routing device via the first outlet, and a second mass spectrometer positioned relative to the second outlet to receive ions exiting the ion routing device via the second outlet.

Abstract: An intravascular catheter for peri-vascular and/or peri-urethral tissue ablation includes multiple needles advanced through supported guide tubes which expand with open ends around a central axis to engage the interior surface of the wall of the renal artery or other vessel of a human body allowing the injection an ablative fluid for ablating tissue, and/or nerve fibers in the outer layer or deep to the outer layer of the vessel, or in prostatic tissue. The system also includes means to limit and/or adjust the depth of penetration of the ablative fluid into and beyond the tissue of the vessel wall. The preferred embodiment of the catheter includes structures which provide radial and lateral support to the guide tubes so that the guide tubes open uniformly and maintain their position against the interior surface of the vessel wall as the sharpened injection needles are advanced to penetrate into the vessel wall.

Abstract: Some embodiments herein are directed to head-mounted Virtual Retina Display (VRD) systems with actuated reflective pupil steering. The display systems include a projection system for generating image content and an actuated reflective optical architecture, which may be part of an optical combiner, that reflects light from the projection system into the user's eyes. The display systems are configured to track the position of a user's eyes and to actuate the reflective optical architecture to change the direction of reflected light so that the reflected light is directed into the user's eyes. The VRDs described herein may be highly efficient, and may have improved size, weight, and luminance such that they are capable of all-day, everyday use.

Abstract: An approach for managing workload deployment in a distributed network, including edge computing is provided. The approach includes deploying several modules, such as, EMM (energy management module), LDM (localized deployment manager) and EDM (edge deployment manager). These modules will be constantly monitoring and managing the energy consumption at the edge nodes under their purview and communicate with other modules to develop a holistic energy management system (e.g., energy policies, energy algorithms, energy plans, etc.) to ensure the most effective energy management of workload is implemented.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: Disclosed herein are glass pharmaceutical vials having sidewalls of reduced thickness. In embodiments, the glass pharmaceutical vial may include a glass body comprising a sidewall enclosing an interior volume. An outer diameter D of the glass body is equal to a diameter d1 of a glass vial of size X as defined by ISO 8362-1, wherein X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1. However, the sidewall of the glass pharmaceutical vial comprises an average wall thickness Ti that is less than or equal to 0.85*s1, wherein s1 is a wall thickness of the glass vial of size X as defined by ISO 8362-1 and X is one of 2R, 3R, 4R, 6R, 8R, 10R, 15R, 20R, 25R, 30R, 50R, and 100R as defined by ISO 8362-1.

Abstract: A braking system includes: brake circuits independently activated and deactivated and when activated apply braking force at respective wheels; a braking stability module detecting an issue or a failure with a first one of the brake circuits where an unexpected amount of braking torque is being applied as compared to an amount of braking torque applied at a second one of the brake circuits, and mitigating effect of the unexpected amount of braking torque on a yaw rate of the vehicle by i) adjusting the braking torque of the first one of the brake circuits, ii) adjusting braking torque of the second one of the brake circuits, and/or iii) deactivating the first one of the brake circuits and modulating braking torque of the second one of the brake circuits, to compensate for the unexpected amount of braking torque.

Abstract: The present invention relates to antibodies that specifically bind to one or more of IL-4, IL-13, IL-33, TSLP, and p40. The present invention further relates to antibodies that bind to one of IL-4, IL-13, IL-33, or TSLP. The invention further relates to multispecific antibodies that specifically bind to IL-4 and IL-13, and at least one other target. The present invention relates to multispecific antibodies that bind IL-4, IL-13, and one of IL-33, TSLP, or p40. The present invention also pertains to related molecules, e.g. nucleic acids which encode such antibodies or multispecific antibodies, compositions, and related methods, e.g., methods for producing and purifying such antibodies and multispecific antibodies, and their use in diagnostics and therapeutics.

Abstract: Systems and methods of the present disclosure include at least one building component detection sensor device configured to be deployed within (or proximate to) a building comprised of a plurality of building components. The at least one building component detection sensor device is configured to detect data relating to at least one building component of the plurality of building components. In addition, a building component property determination system includes a processor configured to execute instructions stored in memory to determine one or more properties of the at least one building component based at least in part on the data detected by the at least one building component detection sensor device.

Abstract: In one example in accordance with the present disclosure, a fluidic die is described. The fluidic die includes a substrate and fluid actuators, the fluid actuators being disposed on the substrate. The fluidic die also includes a bond pad region defined on the substrate. The bond pad region includes a high aspect ratio power delivery bond pad with multiple bonding sites and a high aspect ratio power return bond pad with multiple bonding sites.

Abstract: Apparatus and methods are disclosed for generating, sending, and receiving messages in a networked environment using autonomous (or semi-autonomous) agents. In one example of the disclosed technology, a method of controlling message flow in a computer network comprising a plurality of agents, agent data consumers, and an agent message bridge configured to send messages by receiving a set of messages, at least some of the messages including a message type, queuing the set of messages in a spooler that includes an indication of the respective message type for each of the messages, receive an indication that sending some of the messages queued in the spooler should be delayed for one or more indicated message types, and sending at least one of the messages to a selected one or more of the agent data consumers, the sent messages not being of the indicated message types.